Profile picture for Ronald van Vollenhoven, MD, PhD

Ronald van Vollenhoven, MD, PhD

Professor Ronald F. van Vollenhoven is a rheumatologist at the Department of Rheumatology  and Clinical Immunology, Amsterdam UMC and Director of the Amsterdam Rheumatology  Center in Amsterdam, the Netherlands. 

Dr. Van Vollenhoven’s research interests focus around the development and systematic  evaluation of biological and immunomodulatory treatments for the rheumatic diseases. With  his co-workers, he established the Stockholm registry for biological therapies (the STURE  database) which supported research projects relating to clinical efficacy, pharmacology,  outcomes and pharmacoeconomics. He has been principal investigator in many clinical trials  of novel therapies in rheumatic diseases and has contributed to a number of important  investigator-initiated trials including the SWEFOT, ADMIRE, DOSERA and NORD-STAR trials.  He has published over 450 original papers (H-index: 91), book chapters and reviews, and is  associate-editor of Dubois’ Lupus Erythematosus (Elsevier, 2014), editor of the textbook  Clinical Therapy Research in the Inflammatory Diseases (World Scientific Press, 2015), author  of the monograph Biological Therapy of Rheumatoid Arthritis (Springer, 2015) and co-author,  with Prof. Laurent Arnaud, of the Handbook of Systemic Lupus Erythematosus (Springer,  2017). In 2004, Dr. Van Vollenhoven was awarded the Scandinavian Research Foundation  Prize for excellence in clinical research in rheumatology, he is an honorary member of several  rheumatological societies, and in 2019 he was awarded the Dutch Rheumatology Society’s  highest award, the Jan van Breemen medal. 

Professor Van Vollenhoven is Editor-in-Chief of the on-line journal Lupus Science & Medicine.  He is also the Chair of the EULAR Research Committee, past-chair of the Swedish  Rheumatology Society Professors’ Council, and (co-)initiator of the CERERRA registries  collaboration, the NORD-STAR collaboration for Nordic trials in the rheumatic diseases, and  the Treat-to-Target-in-SLE and DORIS initiatives. 

Articles By Ronald van Vollenhoven, MD, PhD

lupus SLE

Deep remission in SLE – what is it, and can we achieve it?

By Ronald van Vollenhoven, MD, PhD

Recent reports on small numbers of lupus patients treated with CAR-T cells directed against CD19+ B lymphocytes have generated considerable excitement, not so much because the initial response to this therapy was favorable, but because after follow-up durations of two years or longer the patients were reported to have an ongoing clinical remission without the need for further treatment and in the absence of most autoantibodies. This state has been referred to in terms such as “immunological remission” or “resetting the immune system”, suggesting that an important and potentially permanent change had occurred. Perhaps we can call it a Deep Remission, for now. So what is this Deep Remission?

Read Article
choices2.jpg

How I Choose Biologics (Best of 2015)

By Ronald van Vollenhoven, MD, PhD

Clinical decision-making, occurring at the intersection of the ’art’ and the ’science’ of medicine, remains enigmatic and controversial.

Read Article

How I Choose Biologics

By Ronald van Vollenhoven, MD, PhD

Clinical decision-making, occurring at the intersection of the ’art’ and the ’science’ of medicine, remains enigmatic and controversial. 

Read Article
×